Business Wire

Landsvirkjun Provides Power to Secure the Continued Growth of Advania Data Centers

Del

Landsvirkjun and the technology company Advania Data Centers have signed a power purchase agreement for the supply of 30 MW to Advania’s data center in Reykjanesbær. Efforts are being made to expand the data center campus and Advania Data Centers expects to triple its operations in Iceland in the near future.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180227006196/en/

Landsvirkjun provides power to secure the continued growth of Advania Data Centers (Photo: Business  ...

Landsvirkjun provides power to secure the continued growth of Advania Data Centers (Photo: Business Wire)

The power purchase agreement allows Advania Data Centers to meet the ever-increasing demand for high performance computing and specialized blockchain technology services.

The Icelandic climate and renewable energy contribute to a favourable environment for data centers in Iceland. The fact that the data center utilises temperate cold air to cool equipment is an especially attractive attribute to foreign customers of Advania Data Centers. This natural “free air cooling” means that the data centers do not need to utilise large amounts of energy to cool the equipment, minimizes PUE and it is therefore more efficient to operate the data centers in Iceland than it would be elsewhere.

The energy will be delivered from Landsvirkjun's current power station network, consisting of 14 hydropower stations, three geothermal stations and two wind turbines. Landsvirkjun is currently expanding the Búrfell Hydropower Station to meet growing demand for renewable energy in Iceland.

Hörður Arnarson, CEO of Landsvirkjun:

“The collaboration with Advania Data Centers has been successful and it has been a pleasure to see the ongoing success of the company. The company’s success has enabled the growth of a new and innovative industry in Iceland, which pays a competitive price for energy. Iceland is an ideal setting for the operation of data centers and the sale of electricity from renewable energy sources reinforces Landsvirkjun’s own operations while supporting the further growth of the information technology sector in Iceland.”

Eyjólfur Magnús Kristinsson, CEO of Advania Data Centers:

“We have invested heavily in expertise and technical capabilities in recent years to better serve customers with high density hosting needs and this has strengthened the company’s position in a highly competitive environment. Our customers see the benefits of the energy savings that come with the natural air cooling of computer equipment in the data center. A successful cooperation with Landsvirkjun is one of the reasons Advania Data Centers will continue on the fast pace growth track it has been on for the past years. The capability to fulfil continued customer demand for increased service delivery in Iceland is now secured for our next growth phase.”

Advania Data Centers:

Advania Data Centers is a technology company in the field of High Performance Computing, blockchain technology and high-density compute hosting. Advania’s HPC team consists of experts that oversee the operation of HPC environments and HPC Jobs for our customers, globally leading organizations in manufacturing, technology, science among other industries.

Landsvirkjun:

Landsvirkjun is owned by the Icelandic state and produces electricity from renewable energy resources; hydroelectric energy, geothermal energy and wind energy. Long-term agreements, competitive prices, unparalleled security of supply, competitive prices, as well as excellent cable connectivity to Europe and North America and cool climate, make Iceland an ideal location for data centers.

Contact information

Landsvirkjun
Magnús Þór Gylfason, + 354 5159000
Head of Public Relations
Magnus.Thor.Gylfason@landsvirkjun.is

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00Pressemelding

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10Pressemelding

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13Pressemelding

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00Pressemelding

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41Pressemelding

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00Pressemelding

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i